Hyperfine (HYPR) Stock Forecast & Price Target

Hyperfine is attractive fundamentally because its Swoop platform solves a real clinical access problem by enabling portable, ultra-low-field brain imaging without specialized infrastructure, while the newer Model 2 and Optive AI software improve signal capture, scan speed, patient comfort, and image quality. Its commercial footprint is already meaningful, with >200 systems deployed worldwide, about 60% in the U.S., rising utilization in hospitals, and early but expanding adoption in neurology offices and international markets supported by a lean sales model and recurring 5-year service contracts. Financially, the company has delivered >50% gross margins for four consecutive quarters, sold 12 units in Q2, ended with $43.5M in cash and runway into 2028, and retains catalyst-rich growth from contrast label expansion and broader reimbursement pathways.

Hyperfine is viewed negatively because its Swoop adoption remains early, with a small and developing install base that can make quarterly revenue lumpy and leave commercial execution highly uncertain. The company also faces meaningful financing risk because medtech operations are capital intensive, while the guidance midpoint only implies about a 10% year-over-year reduction in cash burn, suggesting the business has not yet reached a self-sustaining scale. In addition, dependence on a limited supplier base, regulatory and reimbursement uncertainty, international expansion risk, and competition from large MRI players could pressure margins, delay growth, and force dilutive capital raises if demand or execution falls short.